Why did Novo Nordisk stock fall so much today?

The company cut 2026 guidance, flagging a 5% to 13% decline in sales and operating profit due to U.S. GLP-1 price reductions and rising competition. Management also warned trends may worsen before improving. That combination lowered confidence in near-term earnings and drove a 17% to 20% share slide.

How do Wegovy price cuts affect the investment case?

Wegovy price cuts reduce realized net price per prescription and compress gross margin. To offset, Novo needs faster volume growth, strong adherence, and cost control. Until price pressure stabilizes, investors should expect lower visibility on revenue and margins and a greater focus on execution metrics each quarter.

What should Swiss investors watch next?

Track U.S. payer contracts, prescription trends for the Wegovy pill, supply updates, and operating expense control. Note the next earnings on 6 May 2026. Consider FX effects if holding ADRs versus Copenhagen shares. Clear signs that net price declines are easing could support a stabilization in sentiment.

Is Novo Nordisk stock attractive after the drop?

Valuation looks more reasonable, with a low-teens P/E and a near 2.5% dividend yield. However, the guidance cut and pricing headwinds mean execution risk is high. Staged buying with strict risk limits makes sense for investors who can handle volatility and wait for clearer margin and volume trends.

Global Market Insights

NVO Stock Today: February 04 — Shares Plunge on 2026 Sales Cut

ByHuzaifa Zahoor February 5, 2026February 5, 2026

Novo Nordisk stock slid sharply on 4 February after management cut its 2026 sales and operating profit outlook by 5% to 13%. Shares of Novo Nordisk (NVO) fell about 17% to 20% as the company flagged steep U.S. GLP-1 price reductions and tougher competition. Leaders warned it may get worse before it gets better, even with a strong Wegovy pill launch. For Swiss investors, the reset highlights revenue visibility, margin pressure, and FX considerations when holding ADRs or Copenhagen-listed shares.